Geron to present real-world claims study of imetelstat in lower-risk MDS at Japan hematology meeting

By Public Technologies
  • Geron flagged new real-world and clinical analyses of imetelstat in lower-risk myelodysplastic syndromes for upcoming presentations in Japan and Europe.
  • Data from US claims are set to show most patients stayed on therapy through early treatment months despite heavy comorbidity.
  • Separate IMerge-derived analyses are expected to indicate durable responses in some patients, with early, generally manageable blood-count suppression.
  • Another presentation will outline evidence that telomerase inhibition may affect disease biology, supporting imetelstat’s positioning beyond symptomatic benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120803PRIMZONEFULLFEED9843834) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.